Navigation Links
Clinical trial success influenced by biomarker- and receptor-targeted therapies in NSCLC
Date:2/14/2014

DENVER Over the past decade, a great clinical focus has been directed at developing new and innovative therapies for advanced non-small cell lung cancer (NSCLC). An analysis of clinical trials evaluating these therapies demonstrates that the cumulative success rate for new agents for advanced NSCLC is lower than the industry-estimated rate. However, biomarker- and receptor-targeted therapies were found to substantially increase clinical trial success.

The analysis was designed to evaluate the risk of clinical trial failure in advanced (stage IIIb-IV) NSCLC drug development over the past 14 years. The success rate was defined as the likelihood that a new drug would pass all phases of clinical trial testing and be approved. Success rates were compared with rates estimated by the biopharmaceutical industry as well as rates determined by risk analysis research in other disease indications.

The success rate for NSCLC drug development was 11%, which is lower than the industry estimate of 16.5%. However, success rates were higher for certain drug indications; the cumulative success rate was 62% for biomarker targeted therapy, which was nearly six times higher than the rate for trials without a biomarker targeted indication (11%). The analysis also showed that success rates became worse with each new phase of testing, which indicates that earlier phase trials may provide little help in ensuring the success of later phase trials.

"The findings suggest that some treatment modalities and drug design strategies may help to decrease drug-development risk and promote the development of innovative drugs to treat advanced NSCLC," says lead author Jayson Parker, PhD, MBA, of the Department of Biology, University of Toronto at Mississauga, Toronto, Ontario, Canada. A report on the findings of the analysis is published in the February issue of the International Association for the Study of Lung Cancer's journal, the Journal of Thoracic Oncology (JTO).

The cumulative success rates for small-molecule and biologic drugs for advanced NSCLC were lower than industry aggregate rates; the rate for small-molecule drugs was 17% (compared with the industry aggregate of 32%) and the rate for biologic drugs was 10% (compared with 13%). When the impact of the mechanism of action was analyzed, the cumulative success rate was 31% for receptor targeted therapies, such as bevacizumab, crizotinib, erlotinib, and gefitinib, which was nearly threefold better than nontargeted therapies (11%). The rate was lowest (6%) for immunotherapy.

"Our analysis suggests that biomarker targeted treatment indications and compounds that have a receptor targeted mechanism of action offer the best chance of clinical success in this indication and should be the focus of future clinical trial development," says first author Adam Falconi, BSc, Pharm, of the Department of Pharmacy, Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Canada. Clinical trials involving the use of biomarkers and receptor targeted therapies should be a priority for patients with advanced NSCLC who wish to enroll in a clinical trial.

The third coauthor of the study, Gilberto Lopes, MD, of Johns Hopkins University School of Medicine, Baltimore, Maryland, and HCor Onco Cancer Center for Hospital do Corao, Brazil, is an IASLC member on the Career Development Committee.


'/>"/>

Contact: Kristin Richeimer
kristin.richeimer@iaslc.org
720-325-2953
International Association for the Study of Lung Cancer
Source:Eurekalert

Related medicine news :

1. First targeted nanomedicine to enter human clinical studies
2. Clinical insight improves treatment with new lung cancer drug
3. Clinical news alert from the American Academy of Orthopaedic Surgeons
4. NYU Langone experts present research, clinical advances at neurosurgeons meeting
5. Kroenke honored for outstanding contributions in clinical research training
6. Awards celebrate clinical research that can improve health and alleviate suffering
7. Association for Psychological Science, SAGE launch Clinical Psychological Science
8. URMC clinical trial tests new regimen for hypertension
9. Analysis Finds Clinical Trials Often Small, of Poor Quality
10. Automated insulin dosage titration system demonstrates positive clinical study results
11. Clinical news alert: Journal of the American Academy of Orthopaedic Surgeons May highlights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... ... February 22, 2017 , ... In a 2012 survey, over ... not filling a prescription because they could not afford to pay for it. ... were 30-60%*. At the same time, hospitals, pharmacies, manufacturers and nursing ...
(Date:2/22/2017)... Colorado (PRWEB) , ... February ... ... the availability of their newest advanced absorption cannabidiol (CBD) serum, “NANOCALM 300” ... delivery system®, which provides instant absorption from the mouth into the bloodstream. ...
(Date:2/22/2017)... WV (PRWEB) , ... February 22, 2017 , ... ... awarded a contract to Quality Insights to help small practices in Delaware, New ... Payment Program, established by the Medicare Access and CHIP Reauthorization Act of 2015 ...
(Date:2/22/2017)... (PRWEB) , ... February 22, 2017 , ... ... communications company, launched a new media platform connecting healthcare technology professionals and other ... be followed by a quarterly publication starting on March 1, announced Michael J. ...
(Date:2/22/2017)... ... February 22, 2017 , ... Pet obesity in the U.S. continued to steadily ... the Association for Pet Obesity Prevention (APOP). During the ninth annual survey, APOP also ... the benefits of corn and grains, value of raw and organic diets, and the ...
Breaking Medicine News(10 mins):
(Date:2/22/2017)... A research report by Arcview Market Research focused on cannabis ... changing landscape of the legal market reveals that regulated cannabis sales ... , a 30% increase from 2015. According to the research ... 2021 representing a 26 percent compound annual growth rate. The use ... Canada is gradually becoming more mainstream thanks ...
(Date:2/22/2017)... LONDON , Feb. 22, 2017  Based ... therapy market, Frost & Sullivan recognizes SnooZeal, Inc. ... SnooZeal is a highly innovative product that intelligently ... training the tongue muscles through the clinically proven ... over-the-counter (OTC) status, SnooZeal is one of the ...
(Date:2/22/2017)... Feb 22, 2017 Research and Markets ... Devices Market (Thermometers - Digital, Infrared, Mercury; Trend Indicator):Analysis By Region, ... ... Market is forecasted to grow at a CAGR of 5.33% during ... prevalence of infectious diseases along with surging demand of digital thermometer. ...
Breaking Medicine Technology: